All In Biotech

Drug Trial Radar · NCT06828055

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Dec 18, 2024

Primary completion

Jun 24, 2025

Study completion Aug 15, 2025

Sponsor

Lead sponsor
Viking Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.

Conditions

  • Weight Loss

Interventions

  • PlaceboDrug

    Matching Placebo to VK2735

  • VK2735Drug

    Active Treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent (relative) change from baseline in body weight after 13 weeks of treatmentTime frame: 13 Weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Viking Clinical Site #111

    Peoria, Arizona

  • Viking Clinical Site #105

    Lake Forest, California

  • Viking Clinical Site #101

    Clearwater, Florida

  • Viking Clinical Site #108

    Largo, Florida

  • Viking Clinical Site #107

    Ocoee, Florida

  • Viking Clinical Site #102

    Port Orange, Florida

  • Viking Clinical Site #100

    Indianapolis, Indiana

  • Viking Clinical Site #110

    Louisville, Kentucky

  • Viking Clinical Site #114

    Marrero, Louisiana

  • Viking Clinical Site #109

    City of Saint Peters, Missouri

  • Viking Clinical Site #112

    Kansas City, Missouri

  • Viking Clinical Site #113

    Butte, Montana

  • Viking Clinical Site #103

    Knoxville, Tennessee

  • Viking Clinical Site #104

    Austin, Texas

  • Viking Clinical Site #106

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.